
Photo: Depositphotos
Aug 12, 2025, 16:18
A Turning Point in H3 K27M-mutant Diffuse Midline Glioma – Jazz Pharmaceuticals
Jazz Pharmaceuticals shared a post on LinkedIn:
“The FDA’s accelerated approval of a treatment for recurrent H3 K27M-mutant diffuse midline glioma is a powerful step forward for the rare cancer community. This milestone shows that innovation is possible, even in the toughest cases like these.
Learn more about what this milestone means for this rare brain cancer.”
More posts featuring Jazz Pharmaceuticals on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 13, 2025, 11:53
Aug 13, 2025, 11:24
Aug 13, 2025, 09:58
Aug 13, 2025, 09:33